Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Date

09 Oct 2016

Session

Poster display

Presenters

Athanassios Argiris

Citation

Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376

Authors

A. Argiris1, M. Gillison2, R.L. Ferris3, K. Harrington4, T.K. Sanchez5, C. Baudelet6, W.J. Geese7, J. Shaw8, R. Haddad9

Author affiliations

  • 1 Medical Oncology, Hygeia Hospital, 151 23 - Athens/GR
  • 2 Internal Medicine, College Of Medicine, The Ohio State University, 43202 - Columbus/US
  • 3 Division Of Head And Neck Surgery Departments Of Otolaryngology, University of Pittsburgh, Eye and Ear Institute, 15213 - Pittsburgh/US
  • 4 Division Of Radiotherapy And Imaging, The Institute of Cancer Research, SW7 6JB - London/GB
  • 5 Global Clinical Research, Oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 6 Biostatistics, Bristol-Myers Squibb, 08540 - Princeton/US
  • 7 Oncology, Bristol-Myers Squibb, 08648 - Lawrence Township/US
  • 8 Clinical Outcomes Assessment And I-o Lcm Worldwide Health Economics And Outcomes Research, Bristol-Myers Squibb, 08540 - Princeton/US
  • 9 Head And Neck Oncology Program , Dana-Farber/Harvard Cancer Center, 02215 - Boston/US
More

Resources

Background

Patients (pts) with recurrent/metastatic (R/M) SCCHN have a poor prognosis. Addition of cetuximab to platinum and 5-FU (Extreme regimen) improved overall survival (OS) vs platinum-fluorouracil alone as first-line (1L) treatment of pts with R/M SCCHN and is a widely accepted standard of care in this setting. However, treatment results remain disappointing with

Trial design

Pts aged ≥18 yr with histologically confirmed R/M SCCHN not amenable to curative therapy who have received no prior systemic therapy for their disease (except chemotherapy given as part of a multimodal treatment regimen that was completed 6 mo or more before enrollment) will be eligible. Approximately 490 pts will be randomized to receive nivo in combination with ipi or the Extreme regimen until progression or unacceptable toxicity. Primary endpoints are OS and progression-free survival. Secondary endpoints are objective response rate, time to symptomatic deterioration based on the 10-item Functional Assessment of Cancer Therapy-Head & Neck Symptom Index, and PD-L1 expression as a predictive biomarker for efficacy.

Clinical trial identification

NCT02741570

Legal entity responsible for the study

Sponsored by Bristol-Myers Squibb.

Funding

Sponsored by Bristol-Myers Squibb.

Disclosure

A. Argiris: Consultant for BMS. M. Gillison: Consultant and clinical trials contract to OSU with Bristol-Myers Squibb. Consultant for Merck Inc and Lilly. R.L. Ferris: Grant received from VentiRx, Bristol-Myers Squibb, and AZ/Medimmune. Member of ad-hoc advisory board for Merck, Celgene, Bristol-Myers Squibb, AZ/Medimmune. K. Harrington: Advisory Board member for BMS, Astra-Zeneca, Merck and Pfizer. T.K. Sanchez, C. Baudelet, W.J. Geese: Employee of Bristol-Myers Squibb. J. Shaw: Employee and shareholder of Bristol-Myers Squibb. R. Haddad: Grants and personal fees received from BMS during the conduct of the study. Grants received from Astra Zeneca, Celgene, and Venti-Rx. Received personal fees from Merck, Pfizer, Celgene, Eisai.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings